Journal Publications

Export 135 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Martin N, Thornton A, Hickman M, Sabin C, Nelson M, Cooke G, Martin T, Delpech V, Ruf M, Price H et al. Clin Infect Dis, 2016 May 01, Volume 62, Issue 9, p.1072-1080, (2016)
Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. Booth J, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar E, Turner-Stokes T, Khatib N, Das P et al. Nephrol Dial Transplant, 2016 Dec, Volume 31, Issue 12, p.2099-2107, (2016)
Efaviranz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. HIV-CAUSAL Collaboration. Cain L, Caniglia E, Phillips A, Olsen A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I et al. Medicine (Baltimore), Volume Oct;95(41):e5133, (2016)
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. The TenoRes Study Group . Lancet Infect Dis, Volume 16, p.565-575, (2016)
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre J, Amieva H, Cabié A, Williams I, Di Perri G, Tellez M et al. HIV Med, 2016 Jun, Volume 17, Issue 6, p.471-8, (2016)
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro M, Günthard H, Wittkop L, Kordossis T, García F et al. J Antimicrob Chemother, 2016 May, Volume 71, Issue 5, p.1352-60, (2016)
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. . AIDS, 2016 Jan 28, Volume 30, Issue 3, p.503-13, (2016)
No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom. White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D and Dunn D. J Infect Dis, 2016 Nov 01, Volume 214, Issue 9, p.1302-1308, (2016)
Predicting virological decay in patients starting combination antiretroviral therapy. . AIDS, 2016 Jul 17, Volume 30, Issue 11, p.1817-27, (2016)
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. Jose S, Quinn K, Dunn D, Cox A, Sabin C and Fidler S. HIV Med, 2016 May, Volume 17, Issue 5, p.368-72, (2016)
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Mocroft A, Lundgren J, Antinori A, Monforte A, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D et al. Euro Surveill, 2015, Volume 20, Issue 47, (2015)
A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK. Mourad R, Chevennet F, Dunn D, Fearnhill E, Delpech V, Asboe D, Gascuel O and Hue S. AIDS, 2015 Sep 24, Volume 29, Issue 15, p.1917-25, (2015)
Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. Huntington S, Thorne C, Newell M, Anderson J, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2015 Apr 24, Volume 29, Issue 7, p.801-9, (2015)
The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. Huntington S, Thorne C, Newell M, Anderson J, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2015 Nov, Volume 29, Issue 17, p.2269-78, (2015)
The contribution of viral genotype to plasma viral set-point in HIV infection. Hodcroft E, Hadfield J, Fearnhill E, Phillips A, Dunn D, O'Shea S, Pillay D and Brown A. PLoS Pathog, 2014 May, Volume 10, Issue 5, p.e1004112, (2014)
The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations. Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C, Gompels M, Gilson R et al. HIV Med, 2014 May, Volume 15, Issue 5, p.311-6, (2014)
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. Klein M, Young J, Dunn D, Ledergerber B, Sabin C, Cozzi-Lepri A, Dabis F, Harrigan R, Tan D, Walmsley S et al. CMAJ Open, 2014 Oct, Volume 2, Issue 4, p.E318-29, (2014)
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. Bulteel N, Bansi-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Sabin C and Nelson M. J Infect, 2014 Jan, Volume 68, Issue 1, p.77-84, (2014)
End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study. Gathogo E, Jose S, Jones R, Levy J, Mackie N, Booth J, Connolly J, Johnson M, Leen C, Williams D et al. J Acquir Immune Defic Syndr, 2014 Oct 01, Volume 67, Issue 2, p.177-80, (2014)
Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. . AIDS, 2014 Jun 01, Volume 28, Issue 9, p.1351-6, (2014)
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. O'Connor J, Smith C, Lampe F, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R et al. AIDS, 2014 Mar 27, Volume 28, Issue 6, p.919-24, (2014)
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. May M, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R et al. AIDS, 2014 May 15, Volume 28, Issue 8, p.1193-202, (2014)
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. Jose S, Hamzah L, Campbell L, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P et al. J Infect Dis, 2014 Aug 01, Volume 210, Issue 3, p.363-73, (2014)
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. . AIDS, 2014 Mar 13, Volume 28, Issue 5, p.773-80, (2014)
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. Jose S, Quinn K, Hill T, Leen C, Walsh J, Hay P, Fisher M, Post F, Nelson M, Gompels M et al. AIDS, 2014 Jun 01, Volume 28, Issue 9, p.1333-9, (2014)